MoonLake Immunotherapeutics (MLTX) Total Liabilities (2020 - 2026)

MoonLake Immunotherapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $146.4 million for Q1 2026.

• On a quarterly basis, Total Liabilities rose 48.31% year-over-year to $146.4 million in Q1 2026; TTM through Mar 2026 was $146.4 million, a 48.31% increase from a year earlier, with the FY2025 full-year figure at $120.0 million, up 388.76% from the prior year.
• Total Liabilities grew to $146.4 million in Q1 2026 per MLTX's latest filing, from $120.0 million in the prior quarter.
• Across five years, Total Liabilities topped out at $206.8 million in Q1 2022 and bottomed at $3.9 million in Q2 2022.
• The 5-year median for Total Liabilities is $14.8 million (2024), against an average of $54.6 million.
• Across the five-year window, Total Liabilities jumped 4962.8% in 2022 and plunged 96.28% in 2023, its largest moves.
• Year by year, Total Liabilities stood at $8.1 million in 2022, then soared by 61.57% to $13.0 million in 2023, then soared by 88.07% to $24.5 million in 2024, then soared by 388.76% to $120.0 million in 2025, then climbed by 22.01% to $146.4 million in 2026.
• Per Business Quant, the three latest MLTX Total Liabilities figures stand at $146.4 million (Q1 2026), $120.0 million (Q4 2025), and $123.1 million (Q3 2025).